---
title: "If You Invested $1000 In Cogent Biosciences Stock 5 Years Ago, You Would Have This Much Today"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/302592277.md"
description: "Cogent Biosciences (NASDAQ:COGT) has outperformed the market over the past five years with an annualized return of 30.65%. An initial investment of $1,000 would have grown to $3,787.77 today, based on a stock price of $31.54. The company currently holds a market capitalization of $5.21 billion. This performance highlights the impact of compounded returns on cash growth over time."
datetime: "2026-10-21T16:45:16.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/302592277.md)
  - [en](https://longbridge.com/en/news/302592277.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/302592277.md)
generator: "portal-rs"
---

# If You Invested $1000 In Cogent Biosciences Stock 5 Years Ago, You Would Have This Much Today

Cogent Biosciences (NASDAQ:COGT) has outperformed the market over the past 5 years by 19.53% on an annualized basis producing an average annual return of 30.65%. Currently, Cogent Biosciences has a market capitalization of $5.21 billion.

**Buying $1000 In COGT:** If an investor had bought $1000 of COGT stock 5 years ago, it would be worth **$3,787.77** today based on a price of $31.54 for COGT at the time of writing.

### Cogent Biosciences’s Performance Over Last 5 Years

![comp_fig](https://imageproxy.pbkrs.com/https://cdn.benzinga.com/files/images/story/2026/10/21/694ffb71c9e5ab8612af26cd96745a0a.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg)

Finally -- what’s the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.

*This article was generated by Benzinga's automated content engine and reviewed by an editor.*

### Related Stocks

- [COGT.US](https://longbridge.com/en/quote/COGT.US.md)

## Related News & Research

- [Cogent Biosciences files for USD 400 million at-the-market stock offering](https://longbridge.com/en/news/295453309.md)
- [Cogent Biosciences Secures Long-Term Bezuclastinib Supply Deal](https://longbridge.com/en/news/297839428.md)
- [GRAPHIC-Take Five: AI trade meets the Fed](https://longbridge.com/en/news/302836715.md)
- [Oracle Stocks Edge Up as $1 Billion Backs AI Partners](https://longbridge.com/en/news/302919901.md)
- [IREN Stock: Why Analysts Still See Over 200% Upside Despite This Week's Plunge](https://longbridge.com/en/news/302922686.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**